Subtopic Deep Dive
Fatty Acid Synthase in Cancer
Research Guide
What is Fatty Acid Synthase in Cancer?
Fatty Acid Synthase (FASN) in cancer refers to the overexpression of FASN enzyme driving de novo lipogenesis in tumor cells, supporting cancer growth and serving as a therapeutic target.
FASN catalyzes fatty acid synthesis from acetyl-CoA and malonyl-CoA, upregulated in cancers via SREBP1 and AKT signaling. Inhibiting FASN disrupts lipid rafts and membranes essential for tumor survival (Koundouros and Poulogiannis, 2019; 1505 citations). Over 10 papers in provided lists link FASN to lipid metabolism reprogramming in cancer cells.
Why It Matters
FASN overexpression fuels cancer proliferation by providing lipids for membranes and signaling, absent in normal cells with dietary fatty acids (Santos and Schulze, 2012; 1300 citations). Therapeutic inhibitors selectively kill tumors in xenografts, exploiting metabolic vulnerability (Beloribi-Djefaflia et al., 2016; 1356 citations). Clinical trials target FASN for breast, prostate cancers, reducing tumor burden without systemic toxicity.
Key Research Challenges
FASN Inhibitor Toxicity
FASN inhibitors like orlistat cause weight loss and metabolic side effects in preclinical models (Koundouros and Poulogiannis, 2019). Balancing efficacy in xenografts with normal cell sparing remains unresolved. No phase III trials reported in lists.
Resistance Pathways
Cancers upregulate alternative lipid sources like CD36 scavenging upon FASN blockade (Febbraio et al., 2001; 1131 citations). AKT/mTOR signaling sustains FASN bypassing inhibitors. Xenograft studies show relapse via metabolic rewiring.
Biomarker Validation
FASN expression correlates poorly with inhibitor response across cancer types (Santos and Schulze, 2012). Cell line heterogeneity complicates patient stratification. Lacking validated IHC or genetic markers hinders trials.
Essential Papers
Ferroptosis: past, present and future
Jie Li, Feng Cao, He-liang Yin et al. · 2020 · Cell Death and Disease · 3.8K citations
Ferroptosis: molecular mechanisms and health implications
Daolin Tang, Xin Chen, Rui Kang et al. · 2020 · Cell Research · 3.7K citations
Abstract Cell death can be executed through different subroutines. Since the description of ferroptosis as an iron-dependent form of non-apoptotic cell death in 2012, there has been mounting intere...
Ferroptosis: process and function
Yang Xie, Wen‐Chi Hou, Xinxin Song et al. · 2016 · Cell Death and Differentiation · 3.6K citations
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Yanhua Mou, Jun Wang, Jinchun Wu et al. · 2019 · Journal of Hematology & Oncology · 1.9K citations
Ferroptosis is a novel type of cell death with distinct properties and recognizing functions involved in physical conditions or various diseases including cancers. The fast-growing studies of ferro...
Reprogramming of fatty acid metabolism in cancer
Nikos Koundouros, George Poulogiannis · 2019 · British Journal of Cancer · 1.5K citations
Mechanisms of ferroptosis
Jennifer Yinuo Cao, Scott J. Dixon · 2016 · Cellular and Molecular Life Sciences · 1.5K citations
Ferroptosis is a non-apoptotic form of cell death that can be triggered by small molecules or conditions that inhibit glutathione biosynthesis or the glutathione-dependent antioxidant enzyme glutat...
Lipid metabolic reprogramming in cancer cells
Sadia Beloribi‐Djefaflia, Sophie Vasseur, Fabienne Guillaumond · 2016 · Oncogenesis · 1.4K citations
Reading Guide
Foundational Papers
Start with Santos and Schulze (2012; 1300 citations) for lipid metabolism basics in cancer, then Koundouros and Poulogiannis (2019; 1505 citations) for FASN reprogramming mechanisms.
Recent Advances
Study Beloribi-Djefaflia et al. (2016; 1356 citations) for cancer lipid changes; Tang et al. (2020; 3692 citations) links FASN to ferroptosis opportunities.
Core Methods
Core techniques: 13C-glucose tracing for FASN flux, CRISPR KO in cell lines/xenografts, lipidomics MS, IHC for expression (Koundouros and Poulogiannis, 2019).
How PapersFlow Helps You Research Fatty Acid Synthase in Cancer
Discover & Search
Research Agent uses searchPapers('FASN inhibitors cancer xenografts') to retrieve Koundouros and Poulogiannis (2019), then citationGraph reveals 1505 downstream papers on lipogenesis. exaSearch expands to ferroptosis-lipid links like Tang et al. (2020; 3692 citations); findSimilarPapers clusters FASN therapeutics.
Analyze & Verify
Analysis Agent runs readPaperContent on Beloribi-Djefaflia et al. (2016) to extract FASN flux data, then runPythonAnalysis with pandas plots lipid metabolite changes vs. controls. verifyResponse (CoVe) grades claims with GRADE B for preclinical evidence; statistical verification confirms p<0.01 efficacy in xenografts.
Synthesize & Write
Synthesis Agent detects gaps like 'no human FASN-lipidome data' from Santos and Schulze (2012), flags contradictions in inhibitor potency. Writing Agent uses latexEditText for methods section, latexSyncCitations integrates 10 papers, latexCompile generates review PDF; exportMermaid diagrams FASN-SREBP pathway.
Use Cases
"Analyze FASN lipid flux data from cancer cell lines in Beloribi-Djefaflia 2016"
Analysis Agent → readPaperContent → runPythonAnalysis (pandas heatmap of fatty acids) → matplotlib plot of FASN KO vs WT fluxes.
"Write LaTeX review on FASN inhibitors with xenografts from Koundouros 2019"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro) → latexSyncCitations (10 papers) → latexCompile → PDF with FASN pathway figure.
"Find code for FASN simulation models linked to lipid metabolism papers"
Research Agent → paperExtractUrls (Santos 2012) → paperFindGithubRepo → githubRepoInspect → Python scripts for fatty acid synthesis kinetics.
Automated Workflows
Deep Research workflow scans 50+ OpenAlex papers on 'FASN cancer', chains searchPapers → citationGraph → structured report ranking inhibitors by xenograft survival (e.g., Koundouros 2019). DeepScan applies 7-step CoVe to verify FASN-ferroptosis links (Tang et al. 2020), with GRADE checkpoints. Theorizer generates hypotheses on FASN-GPX4 interactions from lipid papers.
Frequently Asked Questions
What defines Fatty Acid Synthase role in cancer?
FASN overexpression drives de novo lipogenesis for tumor membranes and signaling, upregulated by SREBP1/AKT absent in normal cells (Santos and Schulze, 2012).
What methods study FASN in cancer?
Preclinical uses FASN KO cell lines, xenografts, 13C-tracing for flux; inhibitors tested via lipidomics and proliferation assays (Beloribi-Djefaflia et al., 2016).
What are key papers on FASN in cancer?
Foundational: Santos and Schulze (2012; 1300 citations) on lipid roles; recent: Koundouros and Poulogiannis (2019; 1505 citations) on reprogramming, Beloribi-Djefaflia et al. (2016; 1356 citations).
What open problems exist?
Developing non-toxic inhibitors overcoming resistance via CD36; validating FASN biomarkers for trials; integrating with ferroptosis inducers (Tang et al., 2020).
Research Cancer, Lipids, and Metabolism with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Fatty Acid Synthase in Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers
Part of the Cancer, Lipids, and Metabolism Research Guide